Solianis Monitoring AG on its Way to Success - Market Entry as Planned in 2011

ZURICH, February 8 - Solianis Monitoring AG presents its Non-Invasive, Continuous
Glucose Monitoring System at the 3rd International Conference on Advanced
Technologies and Treatments for Diabetes (Basel, Switzerland, February 10-13,
2010).

Dr. Andreas Caduff, PhD, Chief Technology Officer of Solianis,
will present the concept of Solianis' proprietary Multisensor Glucose
Monitoring System (MGMS) which in first tests under daily use conditions
performed according expectations.

"We are pleased with this progress," says Mario Stark, CEO of
Solianis. "Currently we are setting up manufacturing and will subject our
final prototype to rigorous clinical tests. These tests are the prerequisite
to obtain CE approval for market entry in Europe in 2011. They will also give
us the assurance that our MGMS is safe and provides people with diabetes with
the information they and their healthcare professionals need. As an
organization, we are expanding from a start-up enterprise towards a company
which takes the responsibility to bring a reliable MGMS to market. Our
ongoing interaction with scientific and clinical experts as well as patient
groups ensures that MGMS becomes a system that meets the day-to-day needs of
people with diabetes, their relatives and healthcare professionals."

Solianis Monitoring AG is a Swiss medical device company
developing an innovative non-invasive Continuous Glucose Monitoring (CGM)
system for people with diabetes, their relatives and health care
professionals. Its unique and proprietary technology is integrated in a
Multisensor Glucose Monitoring System (MGMS) which continuously delivers
information on glucose variations comparable to the minimally invasive
devices currently approved by the FDA.

Solianis was incorporated in May 2005 and has so far been
funded by private investors, the Pioneer Fond of the Zurich Cantonal Bank and
the EGS Beteiligungen AG. Solianis plans to introduce its first product for
insulin dependent patients with diabetes in Europe in 2011, after product
registration.

    Contacts:

    Media:
    Micaela Wochner
    Phone: +41-44-306-80-29
    Mobile: +41-79-431-79-34
    Micaela.wochner@solianis.com

    www.solianis.com

    Investors:
    Mario Stark
    Phone: +41-44-306-80-40
    Mobile: +41-79-542-88-74
    Mario.stark@solianis.com

Contacts: Media: Micaela Wochner, Phone: +41-44-306-80-29, Mobile: +41-79-431-79-34, Micaela.wochner at solianis.com; Investors: Mario Stark, Phone: +41-44-306-80-40, Mobile: +41-79-542-88-74, Mario.stark at solianis.com